Michael Matson

Q: How accurate are Michael Matson's stock ratings?

About 60% of Michael's ratings were profitable over a one-year hold, with an average return of +14.9% per rating, measured by 13Foresight from historical prices.

Q: How is Michael ranked?

Michael Matson is ranked #607 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Needham

Wall Street Analyst

★★★★☆

#607

on 13Foresight · ranked by our own returns

60%

Success Rate

+14.8%

Average Return

49 of 82 calls profitable · -22.5% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 60% of Michael Matson's ratings turned a profit when each position was held for 1 year — averaging +14.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

146 Buy 61 Hold 0 Sell

Michael's Stock Coverage 35 ratings · 2026-09-10

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
ATRC Atricure	Sep 02, 2026	BUY	Strong Buy -7.3% avg upside 13 analysts	$64.00 20.66% Upside	-2.0%	·
MDT Medtronic	Sep 01, 2026	BUY	Buy +9.5% avg upside 38 analysts	$114.00 24.75% Upside	-0.6%	·
ENOV Enovis	Sep 01, 2026	BUY	Strong Buy +248.3% avg upside 39 analysts	$52.00 179.73% Upside	-9.6%	·
TFX Teleflex	Aug 25, 2026	BUY	Buy +39.3% avg upside 20 analysts	$170.00 28.76% Upside	-5.8%	·
HAE Haemonetics	Aug 18, 2026	HOLD	Buy -18.9% avg upside 18 analysts	—	-1.7%	·
IMDX Insight Molecular Diagnostics	Aug 18, 2026	BUY	Buy +33.1% avg upside 10 analysts	$9.00 124.21% Upside	-3.5%	·
PLSE Pulse Biosciences	Aug 17, 2026	BUY	Strong Buy -3.5% avg upside 7 analysts	$58.00 0.79% Upside	+13.2%	·
LUCD Lucid Diagnostics	Aug 13, 2026	BUY	Strong Buy +496.8% avg upside 8 analysts	$3.00 274.09% Upside	-2.6%	·
ICUI ICU Medical	Aug 07, 2026	BUY	Strong Buy +9.1% avg upside 9 analysts	$187.00 19.15% Upside	-9.2%	·
INGN Inogen	Aug 07, 2026	BUY	Hold +374.9% avg upside 7 analysts	$12.00 132.05% Upside	-10.4%	·
RMD Resmed	Aug 07, 2026	HOLD	Buy +4.4% avg upside 27 analysts	—	+8.1%	·
AORT Artivion	Aug 07, 2026	BUY	Strong Buy +63.7% avg upside 8 analysts	$44.00 78.65% Upside	-7.3%	·
ESTA Establishment Labs Holdings	Aug 06, 2026	BUY	Strong Buy +27.3% avg upside 12 analysts	$95.00 31.24% Upside	-4.8%	·
PSNL Personalis	Aug 06, 2026	HOLD	Strong Buy -8.8% avg upside 11 analysts	—	+25.9%	·
STE Steris	Aug 06, 2026	HOLD	Strong Buy +12.1% avg upside 10 analysts	—	-2.8%	·
LIVN LivaNova	Aug 05, 2026	BUY	Strong Buy +1.6% avg upside 15 analysts	$93.00 19.17% Upside	+4.8%	·
ZBH Zimmer Biomet Holdings	Aug 05, 2026	HOLD	Buy +22.5% avg upside 38 analysts	—	-5.8%	·
KIDS OrthoPediatrics	Aug 05, 2026	BUY	Strong Buy +47.1% avg upside 10 analysts	$35.00 62.98% Upside	+0.4%	·
INMD InMode	Aug 05, 2026	HOLD	Buy +31.3% avg upside 9 analysts	—	-2.0%	·
TMDX TransMedics Group	Aug 03, 2026	BUY	Strong Buy +11.8% avg upside 15 analysts	$106.00 24.08% Upside	+5.9%	·
VCYT Veracyte	Jul 31, 2026	BUY	Strong Buy +20.1% avg upside 19 analysts	$69.00 61.03% Upside	-8.2%	·
SYK Stryker	Jul 31, 2026	BUY	Strong Buy +32.7% avg upside 37 analysts	$418.00 53.44% Upside	-15.4%	·
MMSI Merit Medical Systems	Jul 31, 2026	BUY	Strong Buy +13.5% avg upside 15 analysts	$101.00 17.25% Upside	+5.4%	·
CNMD Conmed	Jul 30, 2026	HOLD	Hold +39.5% avg upside 12 analysts	—	+5.0%	·
NEO NeoGenomics	Jul 29, 2026	BUY	Buy +1.3% avg upside 18 analysts	$19.00 8.87% Upside	+13.8%	·
BSX Boston Scientific	Jul 29, 2026	BUY	Strong Buy +51.4% avg upside 38 analysts	$57.00 31.18% Upside	+3.8%	·
PEN Penumbra	Feb 25, 2026	HOLD	Buy +3.6% avg upside 23 analysts	—	-5.6%	·
TSE:SWA Sarama Resources	Apr 05, 2024	HOLD	Hold 1 analyst	—	+100.0%	·
GMED Globus Medical	May 05, 2021	BUY	Strong Buy +25.0% avg upside 24 analysts	$82.00 10.71% Upside	-8.3%	·
SIBN SI-Bone	Mar 18, 2020	BUY	Strong Buy +41.1% avg upside 18 analysts	$27.00 48.72% Upside	+298.9%	·
MDXG MiMedx Group	Dec 06, 2018	HOLD	Strong Buy +126.4% avg upside 17 analysts	—	+517.5%	·
SINT Sintx Technologies	Nov 11, 2016	BUY	Strong Buy +343.1% avg upside 8 analysts	—	·	·
ADMA ADMA Biologics	Nov 06, 2015	BUY	Strong Buy +16.4% avg upside 15 analysts	$1.00 89.34% Downside	-43.5%	·
ISRG Intuitive Surgical	Apr 19, 2013	BUY	Strong Buy +34.5% avg upside 36 analysts	$636.00 76.07% Upside	-15.0%	·
OFIX Orthofix Medical	Apr 17, 2009	SELL	Buy +214.0% avg upside 15 analysts	—	-115.2%	·

🔒 30 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Michael Matson — Frequently Asked Questions

How accurate are Michael Matson's stock ratings?

Based on the calls 13Foresight could measure, about 60% of Michael's ratings were profitable over a one-year hold, with an average return of +14.9% per rating, or -22.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Michael ranked on 13Foresight?

Michael Matson is currently ranked #607 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Michael cover?

Michael most recently has ratings on ATRC, MDT, ENOV, TFX, HAE, IMDX, PLSE, LUCD, ICUI, INGN, RMD, AORT and 23 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Michael Matson

Rating Distribution

Welcome to 13Foresight!